Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
Keyword(s):
Stage 4
◽
We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion was detected on comprehensive tumour somatic mutation profiling. There is ongoing complete response at 10 months after initiation of erdafitinib. Transient central serous retinopathy, grade 2 hyperphosphataemia and diarrhoea were the adverse events encountered.
2005 ◽
Vol 15
(2)
◽
pp. 107-111
◽
2014 ◽
Vol 14
(7)
◽
pp. 928-935
◽
2007 ◽
Vol 25
(29)
◽
pp. 4697-4698
◽
2005 ◽
Vol 23
(28)
◽
pp. 6813-6816
◽